Editas to cut 65% of workforce in strategy shift; shelves lead gene-editing program
Editas Medicine (NASDAQ:EDIT) plans to slash around 180 jobs, or approximately 65% of its workforce, over the next six months ...
STAT2d
Gene-editing field sees another merger, this time between Chroma Medicine and Nvelop Therapeutics
In industry parlance, the deal joins a “delivery” company with a “cargo” company — fusing the two key pieces needed to build ...
STAT1d
Editas Medicine lays off 65% of staff and shelves lead gene-editing program
Editas Medicine said Thursday afternoon it will lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell disease and shifts focus.
MarketWatch1d
Editas Medicine Pivots Gene Editing Strategy, Cutting 65% of Workforce
The Cambridge, Mass.-based company on Thursday said it will now focus on in vivo Crispr-edited medicines based on its researchers recent scientific progress in multiple tissues. At the same time, it ...
The Western Producer11d
Organics continue battle with gene editing
Glacier FarmMedia - The organic sector has a bone to pick with Canadian regulators on their treatment of gene-edited crops.
Serious side effect of using CRISPR-Cas gene scissors uncovered: AZD7648 molecule can destroy parts of genome
Genome editing with various CRISPR-Cas molecule complexes has progressed rapidly in recent years. Hundreds of labs around the ...
sicklecellanemianews10d
Trial of gene-editing therapy into SCD’s cause opens in California
Sites in Los Angeles and near San Francisco California are enrolling people with severe SCD for a trial to test a gene ...
Editas Medicine Shifts Focus to In Vivo Gene Editing
Editas Medicine ( (EDIT) ) just unveiled an announcement.